24
JAN
2011

Northwest Biotherapeutics Resuming Enrollment In Promising 240-Patient Clinical Trial Of DCVax® For Brain Cancer

Posted By :
Comments : Off
Bethesda, MD, January 24, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax® for Glioblastoma multiforme (“GBM”) brain cancer. To date, this trial has been conducted at 13 clinical sites across the U.S., with 33 patients already having...
Read More
04
NOV
2010

Northwest Biotherapeutics Receives Two “Qualified Therapeutic Discovery Project” Grants

Posted By :
Comments : Off
Bethesda, MD, November 4, 2010 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants. The Therapeutic Discovery Project Grant Program was included in the healthcare reform legislation enacted last March, and established a one-time pool of $1...
Read More
14
OCT
2010

Northwest Biotherapeutics To Present At Inaugural Cancer Immunotherapy Conference

Posted By :
Comments : Off
BETHESDA, Md., Oct. 14 — Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:00 p.m. EDT on October 21, 2010, at the New York Academy of Medicine in New York. Dr. Marnix Bosch, Chief Technical Officer, will provide an overview of the Company’s DCVax® technology and unprecedented...
Read More
03
AUG
2010

Long-Term Follow-Up Of DCVax®-Treated Brain Cancer Patients Shows 33% Of Patients Reached 4-Year Survival And 27% Have Reached Or Exceeded 6-Year Survival

Posted By :
Comments : Off
BETHESDA, MD – August 3, 2010 – Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO) today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme (“GBM”), the most rapid and lethal type of brain cancer, were treated with NWBT’s DCVax®-Brain personalized immune therapy. The data through July 1, 2010, show that...
Read More
07
JUL
2010

Northwest Biotherapeutics Raises Funding And Proceeds With Balance Sheet Restructuring

Posted By :
Comments : Off
BETHESDA, MD – July 7, 2010 – Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO), developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company (the “Common Stock”) by a number of private investors, together with purchases of restricted Common...
Read More